|
QLT starts phase 2 study for punctal plug drug delivery system |
|
|
|
|
News -
Nanomedicine and Drug Delivery News Archive
|
|
Monday, 31 March 2008 |
|
QLT announced the initiation of its CORE phase 2 clinical trial to evaluate its latanoprost punctal plug delivery system for the treatment of glaucoma and ocular hypertension.
The human study is a randomized, masked, parallel-group clinical trial involving 60 patients and evaluating three different concentrations of latanoprost.
More information on QLT's punctal drug delivery systems is available in DelScience's report: "Company profile: QLT, Inc.".
Source: QLT, Inc. |
